- Generic pharmaceutical
Celltrion’s biopharmaceutical plants in Songdo, Incheon, Korea operate Asia’s first FDA cGMP-certified animal cell culture facilities. They are capable of producing the full range of products from drug substance(DS) to drug products (DP). To meet constantly rising demand, we increased the capacity of Plant 1 by 50,000 L in 2019, and plant to build Plant 3 in Songdo with a capacity of around 200,000 L.
- Plant 1 100,000L12,500L × 8Line
- Plant 2 90,000L15,000L × 6Line
- Chemical pharmaceutical
Celltrion’s Plant in Cheongju is the company’s development and production base for generic pharmaceutical products. Its manufacturing facilities for oral solid dosage forms have been GMP-certified by regulators in the United States and Europe.
The Plant has an infrastructure capable of supplying tablet and capsule formulations across the world. It is a global total generic production base with supply chain management infrastructure encompassing all packaging and logistics chains.
Cheongju Plant Production Capacity
50 billion tablets
Celltrion is currently expanding production lines at Cheongju Plant for pre-filled syringes and auto-injectors. We also plan to widen our pharmaceutical product portfolios to include injection type products in the future.
- Cheongju Plant Production Capacity 50 billion tablets